A review of the development of complement inhibitors and how the latest GATHER2 data support avacincaptad pegol for the treatment of geographic atrophy.
Back
Avacincaptad Pegol for Geographic Atrophy: The GATHER Trials
Avacincaptad Pegol for Geographic Atrophy: The GATHER Trials
Episodes
All
All
David R. Lally, MD, reviews the duration and patient demographic data of the investigative drug.
Will the complement C5 inhibitor drug receive FDA approval in 2023? Lally discusses this and more on the latest DocTalk.
Advertisement
Advertisement